Hoth Therapeutics shareholders approve director re-election and plan amendment at 2025 annual meeting

Hoth Therapeutics, Inc.

All five director nominees (Knie, Sarnoff, Linsley, Pavell, Camarra) re-elected with strong support.
Ratification of Withum as auditor for FY2025 approved: 4,559,052 for, 247,728 against.
Amendment to 2022 Plan to increase share reserve from 1,091,317 to 3,091,317 shares approved.
Advisory vote on 2024 executive compensation approved: 1,098,368 for, 265,965 against.
Shareholders selected one-year frequency for future advisory votes on executive pay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.